Product Description
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID). Ketorolac works by reducing hormones that cause inflammation and pain in the body. (Sourced from: https://www.uofmhealth.org/health-library/d00273a1)
Mechanisms of Action: COX1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Zyla Life Sciences
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, China, Germany, Italy, Russia, Spain, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Cataract|Mydriasis|Pain, Postoperative
Phase 2: Breast Cancer|Conjunctivitis, Bacterial
Phase 1: Acute Pain|Diabetic Retinopathy
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04505566 |
INSPIRE | P1 |
Active, not recruiting |
Diabetic Retinopathy |
2025-12-01 |
12% |
2024-09-04 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT06273813 |
NOV-1776-CL-101 | P1 |
Not yet recruiting |
Acute Pain |
2024-12-01 |
2% |
2024-02-24 |
Primary Endpoints|Treatments |
NCT06150898 |
KePreSt | P2 |
Recruiting |
Breast Cancer |
2027-04-20 |
2025-06-14 |
Primary Endpoints|Start Date |
|
NCT06616922 |
MIRAKLE | P2 |
Completed |
Conjunctivitis, Bacterial |
2023-06-14 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT05324358 |
NTM-001-CT001 | P3 |
Completed |
Pain, Postoperative |
2024-09-06 |
13% |
2024-09-20 |
|
CTR20191982 |
CTR20191982 | P3 |
Recruiting |
Mydriasis|Cataract|Pain, Postoperative |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |